<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884598</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000636508</org_study_id>
    <secondary_id>HUMCM-CIRAB</secondary_id>
    <secondary_id>EUDRACT-2008-004573-17</secondary_id>
    <nct_id>NCT00884598</nct_id>
  </id_info>
  <brief_title>Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer</brief_title>
  <acronym>CIRAB</acronym>
  <official_title>Cilengitide (EMD121974) in Combination With Whole Brain Radiotherapy in Patients With Brain Metastases From Lung Cancer - a Single-center, Open-label Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cilengitide may stop the growth of brain metastases by blocking blood flow to the&#xD;
      tumor. Radiation therapy uses high energy X-rays to kill tumor cells. Giving cilengitide&#xD;
      together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of cilengitide when&#xD;
      given together with whole-brain radiation therapy in treating patients with brain metastases&#xD;
      from lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Primary&#xD;
&#xD;
             -  To assess the safety and tolerability of daily cilengitide by determining its&#xD;
                dose-limiting toxicity and maximum-tolerated dose when combined with concomitant&#xD;
                fractionated whole-brain radiation therapy in patients with brain metastases from&#xD;
                lung cancer.&#xD;
&#xD;
        -  Secondary&#xD;
&#xD;
             -  To collect evidence of the best overall response rate, overall survival,&#xD;
                brain-specific progression-free survival, and tumor-specific progression-free&#xD;
                survival of these patients.&#xD;
&#xD;
             -  To collect evidence of changes in functional MRI imaging studies at 6 and 12 weeks&#xD;
                after initiation of therapy.&#xD;
&#xD;
             -  To collect evidence of early response by functional MRI (ASL technique) on days 1,&#xD;
                4, and 12, immediately before and after the administration of cilengitide.&#xD;
&#xD;
             -  To collect evidence of changes in neurological and neurocognitive function tests at&#xD;
                6 and 12 weeks after initiation of therapy.&#xD;
&#xD;
             -  To further evaluate the safety and toxicity of the combination of cilengitide and&#xD;
                whole-brain radiation therapy.&#xD;
&#xD;
             -  To further evaluate the pharmacokinetics of cilengitide administered daily.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive oral cilengitide once daily and undergo whole-brain radiotherapy on the same&#xD;
      days. Treatment continues for 2 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients undergo blood sample collection on days 1, 4, 5, and 12 for pharmacokinetic studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 10 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum-tolerated dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-specific progression-free survival (PFS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor-specific PFS</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in functional MRI imaging studies at 6 and 12 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of early response by functional MRI on days 1, 4, and 12</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of neurological and neurocognitive function tests at 6 and 12 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity of the combination of cilengitide and whole-brain radiation therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of cilengitide</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilengitide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed lung cancer (small cell or non-small cell lung cancer)&#xD;
&#xD;
          -  Patient must be eligible for whole-brain radiotherapy&#xD;
&#xD;
          -  Presence of brain metastasis (single or multiple, synchronous or metachronous) from&#xD;
             lung cancer not amenable to surgery or radiosurgery (presence of metastases at any&#xD;
             other site is allowed)&#xD;
&#xD;
          -  No leptomeningeal metastasis or known subarachnoid spread of tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 (ECOG PS 2 allowed if due to the presence of cerebral&#xD;
             metastases and not due to a high peripheral-tumor load or other reasons)&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Adequate hematologic function&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST, ALT, and alkaline phosphatase &lt; 2.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No history of acute or chronic renal disease&#xD;
&#xD;
          -  No other malignancies treated within the past 5 years, except adequately treated&#xD;
             carcinoma in situ of the cervix or basal cell carcinoma of the skin&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No history of coagulation disorder associated with bleeding or recurrent thrombotic&#xD;
             events&#xD;
&#xD;
          -  No peptic ulcer disease within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure, high risk for uncontrolled arrhythmia, or history of&#xD;
             clinically significant coronary heart disease&#xD;
&#xD;
          -  No known alcohol or drug abuse&#xD;
&#xD;
          -  No other significant or acute concomitant disease&#xD;
&#xD;
          -  No dementia or altered mental status&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent corticosteroids allowed if the dosing regimen has ben stable ≥ 5 days&#xD;
&#xD;
          -  Concurrent anticonvulsants allowed if the dosing regimen has been stable for the past&#xD;
             week&#xD;
&#xD;
          -  More than 30 days since prior participation in another clinical trial&#xD;
&#xD;
          -  No concurrent anticoagulation with vitamin K antagonists, therapeutic-dose&#xD;
             anticoagulation with heparin resulting in prolonged PTT, or therapeutic-dose&#xD;
             anticoagulation with low molecular weight heparin (low-dose [i.e. prophylactic], low&#xD;
             molecular weight heparins allowed)&#xD;
&#xD;
          -  No prior whole-brain radiation or radiosurgery&#xD;
&#xD;
          -  No prior antiangiogenic therapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Manegold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center, Department of Surgery</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Manegold, MD</last_name>
      <phone>49-621-383-2199</phone>
      <email>prof.manegold@t-online.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>April 18, 2009</study_first_submitted>
  <study_first_submitted_qc>April 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Christian Manegold</name_title>
    <organization>University Medical Center Mannheim, University of Heidelberg</organization>
  </responsible_party>
  <keyword>adult tumors metastatic to brain</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

